Post by Sarcoidawareness on Oct 15, 2008 9:30:12 GMT -5
FIND A TRIAL
The National Institutes of Health has developed an on-line searchable
database that contains current information on clinical research studies.
Research studies typically provide free care to those who participate.
A summary of these trials is listed below. CLICK HERE
<http://www.clinicaltrials.gov/ct/gui/action/SearchAction?term=Sarcoidos\
is> or visit www.clinicaltrials.gov <http://www.clinicaltrials.gov/>
and search 'sarcoidosis' to find additional information on current
clinical trials.
Studies at the National Institutes of Health (NIH) in Bethesda, Maryland
are free of charge to those who are eligible to participate and willing
to receive treatment at the center. In some cases, travel expenses are
reimbursed.
Location
Trial Descriptions as of August 2008
Cincinnati, Ohio,
University of Cincinnati Use of Armodafinil for Fatigue in Sarcoidosis
This randomized, double blind study is designed to determine the effect
of Armodafinil (Nuvigil) on fatigue and sleep in sarcoidosis. Patients
will have complete detailed questionnaires regarding their fatigue,
sleepiness, and overall quality of life. They will have sleep studies
done at the start and after each half of the study to determine the
effect of therapy on sleepiness(Contact: Carrie Thacker - 513-584-6252
or Stacy Harman, 513-584-2196.)
Bethesda, MD
NHLBI
Atorvastatin to Treat Pulmonary Sarcoidosis
This is a double-blind, placebo-controlled, randomized trial which aims
to determine if atorvastatin administration results in less steroid use
and longer steroid-free intervals in patients with pulmonary sarcoidosis
who require prednisone treatment. (Contact: NIH Patient Recruitment and
Public Liaison Office, 800-411-1222.)
The Netherlands
Maastricht University Role of Proteomics in Diagnosing Sarcoidosis
This observational study has been designed to evaluate the use of a new
technique, called SELDI-TOF mass spectrophotometry, for the diagnosis of
sarcoidosis. This technique enables the analysis of all enzymes present
in the blood of sarcoidosis patients which may hopefully lead to
creating a disease-specific protein-profile that may facilitate the
recognition of sarcoidosis. Contact: Marjolein Drent, 0031-43-3874347.)
Wright State University
Stanford University
Wake Forest University Efficacy Study of Humira in the Treatment of
Cutaneous Sarcoidosis
This is a a Phase II, Multi-Center, Open Label Study to Determine the
Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis.
(Contact: Michael Heffernan, MD 937-224-7546.)
Copenhagen, Denmark
Statens Serum Institut
Bispebjerg Hospital
Rickettsial Genesis to Sarcoidosis in Denmark
The purpose of this study is to find serological and molecular evidence
of an infection with Rickettsia species in Danish patients with
sarcoidosis. (Contact: Claus B Svendsen, MD +45 (32) 68 38 98.)
Cincinnati, Ohio
University of Cincinnati Inhaled Iloprost for Sarcoidosis Associated
Pulmonary Hypertension.
This open label trial, with patients receiving 16 weeks of therapy, will
study the effectiveness of inhaled iloprost for sarcoidosis associated
pulmonary hypertension (SAPAH). (Contact: Robert P Baughman, MD,
513-584-5225.)
Chicago, IL
University of Chicago A Prospective Open-Label Trial of Rituximab in
Progressive Sarcoidosis
This is an open label study of Rituximab in patients with progressive
sarcoidosis to assess the safety and tolerability of Rituximab in this
patient population. The length of the study will be 52 weeks. (Contact:
Misel Ramirez, 773-702-2645.)
Cincinnati, Ohio
University of Cincinnati Double Blind, Randomized Trial of Bosentan for
Sarcoidosis Associated Pulmonary Hypertension (BOSAPAH)
The purpose of this Double Blind, Randomized Trial is to determine if
bosentan (Tracleer) will help sarcoidosis associated pulmonary
hypertension. (Contact: Robert P Baughman, MD 513-584-5225.)
The Netherlands
Maastricht University
University of Tilburg The Influence of Personality on Pulmonary Fibrosis
and Sarcoidosis
The aim of this study is to examine the role of personality factors as
predictors of fatigue, quality of life, prognosis and health care
consumption in sarcoidosis and pulmonary fibrosis. A number of possible
moderators, such as social support, will also be examined aiming to get
a full picture of the relationship between the various factors.
(Contact: Marjolein Drent, MD, PhD, 0031-433877047 )
Norfolk, VA
Virginia Clinical Research, Inc. A Study of Adalimumab to Treat
Sarcoidosis of the Skin
The purpose of this double-blind, randomized, placebo-controlled study
is to determine if adalimumab is an effective for the skin
manifestations of sarcoidosis. (Contact: Robert J Pariser, MD,
757-622-6315.)
Chicago, IL
University of Chicago A Study of the Natural Progression of Interstitial
Lung Disease (ILD)
The purpose of this study is to obtain information on all patients being
cared for by the ILD program in an effort to better understand the
natural course of these diseases. (Contact: Spring Maleckar,
773-834-5864)
Chicago, IL
Northwestern University
Hematopoietic Stem Cell Support in Patients With Refractory Sarcoidosis
This non-randomized, open label study is designed to examine whether
treating patients with high dose cyclophosphamide and ATG, followed by
return of the previously collected blood stem cells will stop the
progression of sarcoidosis. (Contact: Dzemila Spahovic, MD,
312-908-0059)
Newark, NJ
University of Medicine and Dentistry of New Jersey
Pathogen Specific Immunity in Patients With Sarcoidosis
The purpose of this observational study is to assess the lung cells of
healthy volunteers and patients with stage II and III pulmonary
sarcoidosis for pathogen specific memory immunity and gene expression
patterns. (Contact: Matthew Marin, MD, 973-972-6111.)
Bethesda, MD
National Institute of Dental And Craniofacial Research (NIDCR)
Salivary Proteins in Disease and Health
This observational study will examine saliva samples from healthy
volunteers and patients with various diseases to learn more about how
disease affects the mouth and salivary glands. (Contact: NIH Patient
Recruitment and Public Liaison Office, 800-411-1222.)
Bethesda, MD
NHLBI
Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System
Diseases
This observational study will examine bacteria and toxins in the mouth,
lung and digestive system that may be the cause of various diseases or
symptoms.
(Contact: NIH Patient Recruitment and Public Liaison Office,
800-411-1222.)
Bethesda, MD
NHLBI
Role of Genetic Factors in the Development of Lung Disease
This observational study is designed to evaluate the genetics involved
in the development of lung disease by surveying genes involved in the
process of breathing and examining the genes in lung cells of patients
with lung disease.
(Contact: NIH Patient Recruitment and Public Liaison Office,
800-411-1222.)
Multiple Sites
The Netherlands
Database of Interstitial Lung Diseases
This observational study will develop a database with relevant clinical
data and DNA/serum samples from patients patients with interstitial lung
diseases to facilitate future research on the cause of these diseases.
(Contact: J.M.M. van den Bosch, MD, +31306092424.)
Web Sites:
In addition to the trials listed above, CLICK HERE
<http://www.clinicaltrials.gov/ct/gui/action/SearchAction?term=Sarcoidos\
is> or visit www.clinicaltrials.gov <http://www.clinicaltrials.gov/>
and search 'sarcoidosis' to find additional information on current
clinical trials. If you conduct a `Focused Search', you can
learn about those studies on sarcoidosis within your geographical area.
Sarcoidosis clinical trials at the clinical center of the National
Institutes of Health (NIH) in Bethesda, Maryland are free of charge to
those who are eligible to participate and willing to receive treatment
at the center. For more information on these studies, see the NIH
clinical center Web site at: www.cc.nih.gov <http://www.cc.nih.gov/> .
The National Heart, Lung, and Blood Institute (NHLBI) also maintains a
database of current trials. Visit their Patient Recruitment Site
<http://patientrecruitment.nhlbi.nih.gov/Sarcoidosis.aspx> for more
information.
The National Institutes of Health has developed an on-line searchable
database that contains current information on clinical research studies.
Research studies typically provide free care to those who participate.
A summary of these trials is listed below. CLICK HERE
<http://www.clinicaltrials.gov/ct/gui/action/SearchAction?term=Sarcoidos\
is> or visit www.clinicaltrials.gov <http://www.clinicaltrials.gov/>
and search 'sarcoidosis' to find additional information on current
clinical trials.
Studies at the National Institutes of Health (NIH) in Bethesda, Maryland
are free of charge to those who are eligible to participate and willing
to receive treatment at the center. In some cases, travel expenses are
reimbursed.
Location
Trial Descriptions as of August 2008
Cincinnati, Ohio,
University of Cincinnati Use of Armodafinil for Fatigue in Sarcoidosis
This randomized, double blind study is designed to determine the effect
of Armodafinil (Nuvigil) on fatigue and sleep in sarcoidosis. Patients
will have complete detailed questionnaires regarding their fatigue,
sleepiness, and overall quality of life. They will have sleep studies
done at the start and after each half of the study to determine the
effect of therapy on sleepiness(Contact: Carrie Thacker - 513-584-6252
or Stacy Harman, 513-584-2196.)
Bethesda, MD
NHLBI
Atorvastatin to Treat Pulmonary Sarcoidosis
This is a double-blind, placebo-controlled, randomized trial which aims
to determine if atorvastatin administration results in less steroid use
and longer steroid-free intervals in patients with pulmonary sarcoidosis
who require prednisone treatment. (Contact: NIH Patient Recruitment and
Public Liaison Office, 800-411-1222.)
The Netherlands
Maastricht University Role of Proteomics in Diagnosing Sarcoidosis
This observational study has been designed to evaluate the use of a new
technique, called SELDI-TOF mass spectrophotometry, for the diagnosis of
sarcoidosis. This technique enables the analysis of all enzymes present
in the blood of sarcoidosis patients which may hopefully lead to
creating a disease-specific protein-profile that may facilitate the
recognition of sarcoidosis. Contact: Marjolein Drent, 0031-43-3874347.)
Wright State University
Stanford University
Wake Forest University Efficacy Study of Humira in the Treatment of
Cutaneous Sarcoidosis
This is a a Phase II, Multi-Center, Open Label Study to Determine the
Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis.
(Contact: Michael Heffernan, MD 937-224-7546.)
Copenhagen, Denmark
Statens Serum Institut
Bispebjerg Hospital
Rickettsial Genesis to Sarcoidosis in Denmark
The purpose of this study is to find serological and molecular evidence
of an infection with Rickettsia species in Danish patients with
sarcoidosis. (Contact: Claus B Svendsen, MD +45 (32) 68 38 98.)
Cincinnati, Ohio
University of Cincinnati Inhaled Iloprost for Sarcoidosis Associated
Pulmonary Hypertension.
This open label trial, with patients receiving 16 weeks of therapy, will
study the effectiveness of inhaled iloprost for sarcoidosis associated
pulmonary hypertension (SAPAH). (Contact: Robert P Baughman, MD,
513-584-5225.)
Chicago, IL
University of Chicago A Prospective Open-Label Trial of Rituximab in
Progressive Sarcoidosis
This is an open label study of Rituximab in patients with progressive
sarcoidosis to assess the safety and tolerability of Rituximab in this
patient population. The length of the study will be 52 weeks. (Contact:
Misel Ramirez, 773-702-2645.)
Cincinnati, Ohio
University of Cincinnati Double Blind, Randomized Trial of Bosentan for
Sarcoidosis Associated Pulmonary Hypertension (BOSAPAH)
The purpose of this Double Blind, Randomized Trial is to determine if
bosentan (Tracleer) will help sarcoidosis associated pulmonary
hypertension. (Contact: Robert P Baughman, MD 513-584-5225.)
The Netherlands
Maastricht University
University of Tilburg The Influence of Personality on Pulmonary Fibrosis
and Sarcoidosis
The aim of this study is to examine the role of personality factors as
predictors of fatigue, quality of life, prognosis and health care
consumption in sarcoidosis and pulmonary fibrosis. A number of possible
moderators, such as social support, will also be examined aiming to get
a full picture of the relationship between the various factors.
(Contact: Marjolein Drent, MD, PhD, 0031-433877047 )
Norfolk, VA
Virginia Clinical Research, Inc. A Study of Adalimumab to Treat
Sarcoidosis of the Skin
The purpose of this double-blind, randomized, placebo-controlled study
is to determine if adalimumab is an effective for the skin
manifestations of sarcoidosis. (Contact: Robert J Pariser, MD,
757-622-6315.)
Chicago, IL
University of Chicago A Study of the Natural Progression of Interstitial
Lung Disease (ILD)
The purpose of this study is to obtain information on all patients being
cared for by the ILD program in an effort to better understand the
natural course of these diseases. (Contact: Spring Maleckar,
773-834-5864)
Chicago, IL
Northwestern University
Hematopoietic Stem Cell Support in Patients With Refractory Sarcoidosis
This non-randomized, open label study is designed to examine whether
treating patients with high dose cyclophosphamide and ATG, followed by
return of the previously collected blood stem cells will stop the
progression of sarcoidosis. (Contact: Dzemila Spahovic, MD,
312-908-0059)
Newark, NJ
University of Medicine and Dentistry of New Jersey
Pathogen Specific Immunity in Patients With Sarcoidosis
The purpose of this observational study is to assess the lung cells of
healthy volunteers and patients with stage II and III pulmonary
sarcoidosis for pathogen specific memory immunity and gene expression
patterns. (Contact: Matthew Marin, MD, 973-972-6111.)
Bethesda, MD
National Institute of Dental And Craniofacial Research (NIDCR)
Salivary Proteins in Disease and Health
This observational study will examine saliva samples from healthy
volunteers and patients with various diseases to learn more about how
disease affects the mouth and salivary glands. (Contact: NIH Patient
Recruitment and Public Liaison Office, 800-411-1222.)
Bethesda, MD
NHLBI
Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System
Diseases
This observational study will examine bacteria and toxins in the mouth,
lung and digestive system that may be the cause of various diseases or
symptoms.
(Contact: NIH Patient Recruitment and Public Liaison Office,
800-411-1222.)
Bethesda, MD
NHLBI
Role of Genetic Factors in the Development of Lung Disease
This observational study is designed to evaluate the genetics involved
in the development of lung disease by surveying genes involved in the
process of breathing and examining the genes in lung cells of patients
with lung disease.
(Contact: NIH Patient Recruitment and Public Liaison Office,
800-411-1222.)
Multiple Sites
The Netherlands
Database of Interstitial Lung Diseases
This observational study will develop a database with relevant clinical
data and DNA/serum samples from patients patients with interstitial lung
diseases to facilitate future research on the cause of these diseases.
(Contact: J.M.M. van den Bosch, MD, +31306092424.)
Web Sites:
In addition to the trials listed above, CLICK HERE
<http://www.clinicaltrials.gov/ct/gui/action/SearchAction?term=Sarcoidos\
is> or visit www.clinicaltrials.gov <http://www.clinicaltrials.gov/>
and search 'sarcoidosis' to find additional information on current
clinical trials. If you conduct a `Focused Search', you can
learn about those studies on sarcoidosis within your geographical area.
Sarcoidosis clinical trials at the clinical center of the National
Institutes of Health (NIH) in Bethesda, Maryland are free of charge to
those who are eligible to participate and willing to receive treatment
at the center. For more information on these studies, see the NIH
clinical center Web site at: www.cc.nih.gov <http://www.cc.nih.gov/> .
The National Heart, Lung, and Blood Institute (NHLBI) also maintains a
database of current trials. Visit their Patient Recruitment Site
<http://patientrecruitment.nhlbi.nih.gov/Sarcoidosis.aspx> for more
information.
